

1 **Risk reducing early salpingectomy and delayed oophorectomy as a two staged alternative for**  
2 **primary prevention of ovarian cancer in increased risk women: a commentary**

3

4 **Authors**

5 Faiza Gaba<sup>1,2</sup> , Jurgen Piek<sup>3</sup>, Usha Menon<sup>4</sup>, \*Ranjit Manchanda<sup>1,2,4</sup>

6 <sup>1</sup>Barts Cancer Institute, Queen Mary University of London, Old Anatomy Building, Charterhouse  
7 Square, London, EC1M 6BQ, UK

8 <sup>2</sup>Department of Gynaecological Oncology, St Bartholomew's Hospital, London, UK, EC1A 7BE

9 <sup>3</sup>Department of Gynaecological Oncology, Catharina Hospital, Eindhoven, the Netherlands

10 <sup>4</sup>Department of Women's Cancer, Institute for Women's Health, University College London, London  
11 W1T &DN

12 **\*Corresponding author**

13 Dr Ranjit Manchanda

14 Barts Cancer Institute, Queen Mary University of London,

15 Old Anatomy Building, Charterhouse Square, London, EC1M 6BQ, UK

16 Fax: 0203 594 2792

17 Email: [r.manchanda@qmul.ac.uk](mailto:r.manchanda@qmul.ac.uk)

18

19 **Shortened title:** RRESDO commentary

20

21 **Word count: 1848**

22 Ovarian cancer (OC) is the leading cause of death from gynaecological malignancies in the UK. Despite  
23 considerable funding to develop new treatments, 10-year survival remains poor at ~30%. This  
24 translates into 4,271 deaths annually in the UK, 42,700 in Europe and 152,000 deaths annually  
25 worldwide. High (e.g.-*BRCA1/BRCA2*) and moderate (e.g.-*RAD51C/RAD51D/BRIP1*) penetrance gene-  
26 mutations account for most of the known hereditary-risk of OC. At least 10% of women with epithelial-  
27 OC carry these germline mutations. *BRCA1/BRCA2* carriers have a 17%-44% risk of OC and 65-72% risk  
28 of breast cancer (BC), while *RAD51C/RAD51D/BRIP1* carriers have a 6-11% risk of OC. Primary surgical  
29 prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) remains the most effective  
30 option and gold-standard for OC-risk reduction, particularly given the lack of an effective national OC-  
31 screening programme. The role of RRSO for primary surgical prevention has expanded to include not  
32 just *BRCA1/BRCA2* carriers but also women at intermediate-risk ( $\geq 4$ -5% lifetime-risk of OC). RRSO  
33 reduces OC-risk by 80-96%. Whilst initial data suggested pre-menopausal RRSO reduced BC-risk by  
34 half, more recent publications have questioned this.<sup>1</sup> Nevertheless, RRSO reduces all-cause (HR=0.40,  
35 95%CI:0.26-0.61), BC-specific (HR=0.44, 95%CI:0.26-0.76), and OC-specific (HR=0.25, 95%CI:0.08-0.75)  
36 mortality.<sup>2</sup>

### 37 **Limitations of premenopausal RRSO:**

38 Premenopausal RRSO leads to premature surgical menopause which has detrimental long-term health  
39 consequences. It is associated with an increased risk of heart-disease, stroke, osteoporosis, vasomotor  
40 symptoms, mood changes, sleep disturbance, reduced libido, vaginal dryness, sexual-dysfunction and  
41 neurocognitive decline, especially if unable to use hormone-replacement-therapy (HRT). A 3.03%  
42 absolute increased-risk of cardiovascular mortality has been reported with premenopausal  
43 oophorectomy without HRT (NNH=1:33). *BRCA*-carriers who have estrogen-receptor positive BC  
44 cannot take HRT. Additionally, vasomotor symptoms and sexual-dysfunction are not fully alleviated  
45 by HRT, with symptom levels remaining above those who retain their ovaries. Consequently many

46 women choose to delay RRSO until after menopause. Furthermore, RRSO has a 1.5-5% complication  
47 rate.

#### 48 **Role of fallopian-tube in etiopathogenesis of OC**

49 Following initial observations in *BRCA*-mutation carriers,<sup>3</sup> there is now broad acceptance of the role  
50 of the fallopian-tube in the etiopathogenesis of epithelial-OC. Genotoxic injury leads to p53-mutations  
51 and loss of p53-function (represented by p53-signatures) in the distal fallopian-tube. High-grade  
52 serous ovarian cancers (HGSOC) may develop through further DNA damage from the combined  
53 functional loss of p53 and *BRCA* (or related pathways) or through epigenetic reprogramming. A  
54 precursor lesion called serous-tubal-intraepithelial-carcinoma (STIC) has been defined which is  
55 present as a continuum with early tubal carcinomas, supporting transition from one to another. STICs  
56 have been reported in up to 60% of sporadic HGSOC as well and in 92% of cases have identical TP53  
57 gene-mutations to concurrent pelvic serous carcinomas. Molecular profiling supports the common  
58 origin of STICs/HGSC from the distal tube. Occult STIC/invasive tubal cancers occur in 5-8% of RRSO  
59 specimens from *BRCA*-mutation carriers. Around 70% of these lesions were found in the distal-tube  
60 and not the ovary.

#### 61 **Risk-reducing early-salpingectomy and delayed oophorectomy (RRESDO)**

62 The acceptance of a central role for the tube in OC etiopathogenesis coupled with the detrimental  
63 health sequelae of premature menopause, has led to the attractive proposal of a two-step alternative  
64 OC surgical prevention strategy in pre-menopausal women at increased (high/intermediate) OC-risk  
65 who have completed their family but decline or wish to delay RRSO. It involves early-salpingectomy  
66 (ES) as the first-step followed by delayed-oophorectomy (DO) after menopause. RRESDO has the  
67 advantage of providing a level of risk reduction whilst conserving ovarian function and avoiding  
68 negative side-effects/health-consequences of premature menopause. We reviewed the literature for  
69 ES and DO for OC prevention. Appendix-S1 describes the search strategy and Figure-S1 the flow-chart  
70 of results. Searches were performed in MEDLINE, EMBASE, Pubmed, CINAHL, PsychINFO and clinical-

71 trial registries (ISRCTN, clinicaltrials.gov). Table-1 lists the current studies reporting outcomes of  
72 RRESDO.<sup>4-11</sup> The quality of studies were assessed using the MINORS (Methodological Index for Non-  
73 Randomized Studies) checklist and CASP (Critical Appraisal Skills Programme) qualitative-research  
74 checklist.

## 75 **Acceptability**

76 Data on putative acceptability of RRESDO amongst women at high-risk of OC are limited to one small  
77 questionnaire study and one qualitative study in *BRCA1/BRCA2* carriers.<sup>4, 8</sup> Interest in RRESDO has  
78 been reported in 34% of women in a US survey (n=204)<sup>8</sup> and 44% in a Dutch qualitative study (n=39).<sup>4</sup>  
79 35%-44% women were reported as being unsure about RRESDO and 12%-30% as disinterested.<sup>4, 8</sup> A  
80 recent non-randomised, prospective cohort, pilot study (n=43) with three study arms (RRESDO, RRSO,  
81 screening) found 28% uptake rate for RRESDO.<sup>11</sup> There are no data on acceptability of RRESDO in  
82 intermediate OC-risk women eligible for surgical prevention. A multicentre, prospective, UK study is  
83 evaluating views of high and intermediate-risk women (ISRCTN12310993). A UK-study found 60% of  
84 gynaecological oncologists and geneticists favoured offering RRESDO to pre-menopausal high-risk  
85 women declining RRSO, along-with strong support for a clinical-trial and creation of a UK-wide registry  
86 with ~80% favouring these options.<sup>5</sup> A Dutch qualitative-study also found high acceptability amongst  
87 health professionals for a clinical-trial.<sup>4</sup>

## 88 **Benefits/facilitators and barriers/risks: RRESDO**

89 The main reason for undergoing RRESDO reported by women at high OC-risk and health professionals  
90 is the ability to obtain some OC-risk reduction whilst avoiding detrimental consequences of early  
91 menopause.<sup>4, 5, 8</sup> Barriers to participation for patients included surgical complications, potential  
92 ovarian damage, family-history, previous BC, surgical costs, seriousness of OC and uncertainty on level  
93 of benefit obtained from early salpingectomy (ES) and poor pre-operative counselling of negative side-  
94 effects of RRSO.<sup>4</sup> Barriers perceived by health-professionals included need for two operations, lack of  
95 precision of OC-risk reduction, ease of decision to undergo RRSO, health-care costs, potential loss of

96 reduction in BC-risk, need for long-term follow-up with possible attrition from DO. Interestingly  
97 potential lack of BC-risk reduction was not raised by patients<sup>4</sup> and this in itself has become uncertain  
98 with recent reports finding no benefit of reduction in BC from RRSO. Although RRESDO involves two  
99 surgical procedures, preliminary evidence indicates that most women would find two procedures  
100 acceptable.<sup>8,11</sup>

#### 101 **Other Outcomes**

102 Preliminary pilot-data from a small study of 43 BRCA-mutation carriers suggests, RRESDO and RRSO  
103 are both associated with decreased cancer worry and RRESDO is associated with reduced anxiety at  
104 12-months follow-up.<sup>11</sup> One study suggests that RRESDO may be cost-effective compared to RRSO for  
105 a base-case with a utility-score for RRSO=0.82 and for ES=0.99, level of OC-risk reduction=60% and no  
106 attrition from DO. However, more recent data reports a RRSO utility-score of 0.95, the actual disutility  
107 for ES is unknown, the precise level of OC-risk reduction is unknown, and potential attrition from DO  
108 is missing, which together maintain uncertainty around the comparative cost-effectiveness of  
109 RRESDO.

#### 110 **RRESDO should only be offered in a Clinical Trial/Research Study**

111 Lack of clarity on several key issues strengthens the case to currently offer RRESDO within a research  
112 setting. The extent of OC-risk reduction and long-term health outcomes with ES remain unclear. While  
113 two retrospective population studies found a 35–42% reduction in OC-risk with salpingectomy in low-  
114 risk women, these studies were limited by: indication and detection bias, wide confidence-intervals,  
115 small number of OC cases in salpingectomy subgroups and lack of adjustment for contraceptive pill  
116 use. Besides results from the low-risk population cannot be directly extrapolated to high-risk women.  
117 Salpingectomy will not prevent OC arising outside the tube or within tubal epithelium lined inclusion  
118 cysts. Residual fimbrial tissue implants may remain on the ovarian surface after salpingectomy in 10%  
119 of cases,<sup>12</sup> and could become a potential site for malignant transformation. OC etiopathogenesis is  
120 complex and our current understanding of this is incomplete. There are different types of STIC and the

121 natural history, progression rates, outcomes and rate-limiting step in development of OC associated  
122 with each type is unknown. Moreover, STICs may not be precursors to all HGSOC cases. The long-term  
123 impact of salpingectomy on ovarian function and premature menopause is unknown. Although short-  
124 term data show no detrimental outcome for hormonal levels, blood-flow indices or surgical risks,  
125 these correlate more with fertility outcomes, and are not predictive of menopause. No validated  
126 hormonal criteria predicting duration of menopausal transition or time of final menstruation exist and  
127 only long-term assessments of hormonal levels/menstrual cycles can clarify this.

128 Concerns exist amongst clinicians regarding attrition from DO. A proportion who do not undergo DO  
129 may develop OC. Uncertainties remain around the cost-effectiveness of RRESDO. There is need for  
130 standardisation of protocols for management and follow-up of (isolated) STIC lesions both at national  
131 and international levels. A suggested management protocol is given in Table-2, Supplementary Figure  
132 S2. We reviewed the literature on management of STIC (Table-3) and found a limited evidence base.  
133 Isolated STIC was found in 2% (82/4,149) and occult invasive cancers in 2.2% (93/4,149) of women  
134 undergoing RRSO. We recommend bilateral salpingo-oophorectomy in isolated STIC with negative-  
135 cytology but full staging in those with positive-cytology or an abnormal staging CT-scan. Implementing  
136 RRESDO within a research setting would also enable the development of a tissue-&-data bio-resource  
137 for translational research and secondary studies.

### 138 **Research studies offering RRESDO**

139 There are currently five important non-randomised trials investigating aspects of RRESDO being  
140 undertaken in France, the Netherlands, US and UK. (Table-4). Randomised studies for surgical  
141 prevention are not feasible or ethical in high-risk women. The ongoing studies vary with respect to  
142 primary outcomes, design and sample sizes. The French (Fimbriectomy) study is powered on OC/PPC  
143 incidence, while the others are powered on menopause-related quality-of-life (Dutch), DO uptake (US)  
144 and sexual function (UK, US). The French study does not involve DO. DO is undertaken in the Dutch  
145 TUBA (TUBectomy with delayed oophorectomy to improve quality-of-life as alternative for risk-

146 reducing salpingo-oophorectomy in BRCA1/2 mutation carriers) study at 40-45 years in BRCA1 and 45-  
147 50 years in BRCA2 carriers; and in the US PSDO (Prophylactic-Salpingectomy-with-Delayed-  
148 Oophorectomy) study three years after ES. DO is undertaken in premenopausal women well before  
149 onset of menopause in the US and Dutch studies. In the UK PROTECTOR (Preventing Ovarian Cancer  
150 through early Excision of Tubes and late Ovarian Removal) study DO is undertaken at menopause but  
151 offered earlier for those women who may choose to do so. Similarly, in the US WISP (Women Choosing  
152 Surgical Prevention Trial) study, women are given the choice as to when to undergo DO but are  
153 encouraged to have this done between 40-50 years. While the Dutch and the US PSDO-study only  
154 include BRCA-carriers, the French study also includes women ascertained using FH. The UK study  
155 includes high and intermediate risk women: BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 carriers and FH  
156 based assessment. The WISP-study in addition offers RRESDO to  
157 PALB2/BARD1/MSH2/MSH6/MLH1/PMS2/EPCAM mutation carriers. However mutations in the Lynch  
158 syndrome genes are predominantly associated with an increased risk of non-serous epithelial-OC. In  
159 addition, there is insufficient evidence (lack of validated data) linking PALB2/BARD1/EPCAM/PMS2  
160 mutations with OC.

## 161 **Conclusion**

162 RRSO remains the gold-standard for surgical prevention in women at increased risk of OC. RRESDO is  
163 an alternative for women who have completed their family and prefer to decline or delay  
164 premenopausal RRSO. In the absence of long-term prospective outcome data, and unaddressed  
165 knowledge gaps highlighted above, RRESDO should only be offered within the controlled environment  
166 of a clinical-trial/research study. It is vital clinicians offer appropriate counselling on the advantages  
167 and limitations of salpingectomy versus standard RRSO for informed decision making and consent.  
168 Long-term follow-up is essential to minimise attrition from DO. As data from ongoing trials emerge it  
169 will help inform national and international guidelines on an early-salpingectomy and delayed-  
170 oophorectomy strategy in women at increased risk of OC.

171 **Disclosure of Interests**

172 RM declares research funding from Barts and The London Charity and Roseetrees Trust for the  
173 PROTECTOR Study and is Chief Investigator. RM declares research funding from The Eve Appeal,  
174 Cancer Research UK and from Barts & the London Charity outside this work, as well as an honorarium  
175 for grant review from Israel National Institute for Health Policy Research. FG is the study coordinator  
176 for the PROTECTOR study. JP declares no conflict of interest. UM has a financial interest in Abcodia  
177 Ltd., a company formed to develop academic and commercial development of biomarkers for  
178 screening and risk prediction.

179 **Contribution to authorship**

180 Literature search: FG

181 Preparation of tables and figures: FG, RM

182 Initial draft of manuscript: FG, RM

183 Manuscript writing and approval: FG, JP, UM, RM

184

185 **Funding**

186 No funding was received for this commentary.

187

188

189

190

191

192



193 **References**

- 194 1. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collee JM, van Doorn  
195 HC, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers:  
196 revisiting the evidence for risk reduction. *J Natl Cancer Inst.* 2015 May;107(5).
- 197 2. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-  
198 reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *Jama.* 2010  
199 Sep 01;304(9):967-75.
- 200 3. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic  
201 changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian  
202 cancer. *J Pathol.* 2001 Nov;195(4):451-6.
- 203 4. Arts-de Jong M, Harmsen MG, Hoogerbrugge N, Massuger LF, Hermens RP, de Hullu JA. Risk-  
204 reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: patients' and  
205 professionals' perspectives. *Gynecologic oncology.* 2015 Feb;136(2):305-10.
- 206 5. Chandrasekaran D, Menon U, Evans G, Crawford R, Saridogan E, Jacobs C, et al. Risk reducing  
207 salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic  
208 counsellors and gynaecological oncologists in the UK. *Fam Cancer.* 2015 Dec;14(4):521-30.
- 209 6. Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, et al. Practice Patterns of Hereditary  
210 Ovarian Cancer Management in Korea. *International journal of gynecological cancer : official journal  
211 of the International Gynecological Cancer Society.* 2017 Jun;27(5):895-9.
- 212 7. Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, et al. Early  
213 salpingectomy (TUBectomy) with delayed oophorectomy to improve quality of life as alternative for  
214 risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-  
215 randomised multicentre study. *BMC cancer.* 2015 Aug 19;15:593.
- 216 8. Holman LL, Friedman S, Daniels MS, Sun CC, Lu KH. Acceptability of prophylactic  
217 salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers.  
218 *Gynecol Oncol.* 2014 May;133(2):283-6.
- 219 9. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic  
220 salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. *Obstet  
221 Gynecol.* 2013 Jan;121(1):14-24.
- 222 10. Leblanc E, Narducci F, Farre I, Peyrat JP, Taieb S, Adenis C, et al. Radical fimbriectomy: a  
223 reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA  
224 1 or 2 genes? Rationale and preliminary development. *Gynecologic oncology.* 2011 Jun 1;121(3):472-  
225 6.
- 226 11. Nebgen DR, Hurteau J, Holman LL, Bradford A, Munsell MF, Soletsky BR, et al. Bilateral  
227 salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women  
228 with BRCA1/2 mutations. *Gynecol Oncol.* 2018 May 4.
- 229 12. Gan C, Chenoy R, Chandrasekaran D, Brockbank E, Hollingworth A, Vimplis S, et al.  
230 Persistence of fimbrial tissue on the ovarian surface after salpingectomy. *Am J Obstet Gynecol.* 2017  
231 Oct;217(4):425.e1-.e16.

232

233

**Table-1: Studies reporting RRESDO outcomes**

Publication	Country	Sample size (n)	Study design	Population	Intervention	Outcomes	Follow up	Quality of methodology
Arts-de Jong, 2015	The Netherlands	62	Qualitative study	BRCA1/BRCA2 mutation carriers; health professionals <sup>‡</sup>	Focus group interviews; semi-structured in-depth interviews	Putative acceptability, barriers and facilitators	NA	Good <sup>~</sup>
Chandrasekaran, 2015	UK	173	Prospective cohort survey study	Health professionals <sup>€</sup>	Online questionnaire	Putative acceptability	NA	15/16*
Choi, 2017	South Korea	54	Cross-sectional cohort study	Health professionals <sup>#</sup>	Online/paper questionnaire	Putative acceptability	NA	14/16*
Harmsen, 2015 (study protocol)	The Netherlands	510	Multicentre, prospective, cohort study	BRCA1/BRCA2 mutation carriers, premenopausal, >25 years	RRESDO RRSO	Menopause specific QoL	15 years	21/24*
Holman, 2014	US	204	Prospective cohort survey study	BRCA1/BRCA2 mutation carriers	Online questionnaire	Putative acceptability	NA	15/16*
Kwon, 2013	Canada	2,300	Markov Monte Carlo simulation model	Hypothetical cohort of BRCA1/BRCA2 mutation carriers	RRESDO RRES RRSO	Incremental cost effectiveness ratio per quality adjusted life year	NA	NA
Leblanc, 2011	France	14	Single centre, prospective, cohort study	BRCA1/BRCA2 mutation carriers	Radical fimbriectomy	Optimum surgical technique to minimise complications and ensure high quality specimens for histopathological examination	Not reported	13/16*
Nebgen, 2018	US	43	Multicentre, prospective, cohort, pilot study	BRCA1/BRCA2 mutation carriers, premenopausal, 30-47 years	RRESDO RRSO Screening	Acceptability, surgical outcomes, QoL, cancer specific worry, anxiety, sexual function, body image and menopausal symptoms	12 months	22/24*

RRESDO – risk reducing early salpingectomy and delayed oophorectomy; OC – ovarian cancer; QoL – quality of life; RRSO – risk reducing salpingo-oophorectomy; RRES – risk reducing early salpingectomy

<sup>‡</sup>Gynaecological oncologists; clinical geneticists; breast surveillance practitioners: medical oncologists, surgeons, medical doctors, nurses

<sup>€</sup>Gynaecological oncologists; general obstetricians & gynaecologists; clinical geneticists; genetic counsellors

<sup>#</sup>Members of the Korean Society of Gynecologic Oncology and attendants of the inaugural Hereditary Gynecologic Cancer Symposium in South Korea

<sup>~</sup>Quality of methodology assessed using the CASP (Critical Appraisal Skills Programme) qualitative research checklist

\*Quality of methodology assessed using the MINORS (Methodological Index for Non-Randomized Studies) checklist

**Table-2: Suggested management and follow up of STIC<sup>#</sup> lesions (without invasion)**

Histopathology and Cytology	Management		
	Staging CT Chest, abdomen, pelvis	Surgical staging*	Panel genetic testing** (BRCA1/BRCA2/RAD51C/ RAD51D/BRIP1)
STIC with positive cytology	☑	☑	☑
STIC with negative cytology	☑	Not indicated unless abnormality on CT suggesting otherwise	☑
STIC with missing cytology	☑	Not indicated unless abnormality on CT suggesting otherwise	☑

#All cases of isolated STIC identified at salpingectomy alone (patients undergoing early salpingectomy) should have completion oophorectomy

\*Hysterectomy, omentectomy, pelvic/para-aortic lymphadenectomy (excision of all visible disease)

\*\*If not previously undertaken

**Table-3: Studies reporting the management of STIC lesions in women at increased risk of ovarian cancer**

Publication	Sample size (n)	Median follow up in months (range)	Isolated STIC			Occult invasive cancers	Staging for isolated STIC*			Chemotherapy			STIC recurrence		
			Negative Cytology	Positive cytology	No cytology		Negative Cytology	Positive cytology	No cytology	Negative Cytology	Positive cytology	No cytology	Negative Cytology	Positive cytology	No cytology
Conner, 2014	385	60 (12-96)	6	2	0	17	3	1	0	3	0	0	1 <sup>#</sup>	0	0
Manchanda, 2011	308	Not reported	6	3	0	5	0	3	0	0	0	0	0	0	0
Powell, 2013	405	80 (40-150)	14	3	0	15	7	3	0	2	2	0	1 <sup>~</sup>	0	0
Finch, 2006	159	Not reported	1	0	0	6	0	0	0	0	0	0	0	0	0
Carcangiu, 2006	50	26.5 (1-145)	2	0	1	3	0	0	0	0	0	0	0	0	0
Lamb, 2006	113	29	3	1	0	3	3	1	0	1	1	0	0	0	0
Medeiros, 2006	13	Not reported	0	1	2	2	0	1	2	0	0	0	0	0	0
Callahan, 2007	122	Not reported	2	1	0	4	0	0	0	2	1	0	0	0	0
Reitsma, 2013	360	60 (0-144)	3	0	0	4	0	0	0	0	0	0	0	0	0
Wethington, 2013	593	28 (16-44)	11	1	0	0	6	1	0	0	0	0	0	0	0
Sherman, 2014	966	Not reported	4	0	0	21	0	0	0	0	0	0	0	0	0
Zakhour, 2016	257	79 (20-138)	9	0	0	4	0	0	0	0	0	0	2 <sup>£</sup>	0	0
Poon, 2016	138	79 (45-108)	1	1	1	2	0	0	0	0	0	0	0	0	0
Hirst, 2009	45	Not reported	0	0	1	4	0	0	0	0	0	0	0	0	0
Van der Hoeven, 2018	235	78 (59-96)	0	0	2	3	0	0	0	0	0	0	0	0	1 <sup>§</sup>
<b>Total (n)</b>	<b>4,149</b>	<b>-</b>	<b>62</b>	<b>13</b>	<b>7</b>	<b>93</b>	<b>19</b>	<b>10</b>	<b>2</b>	<b>8</b>	<b>4</b>	<b>0</b>	<b>4</b>	<b>0</b>	<b>1</b>
<b>Total (%)</b>	<b>-</b>	<b>-</b>	<b>2.0</b>			<b>2.2</b>	<b>0.7</b>			<b>0.3</b>			<b>0.1</b>		

\*No upstaging reported in 31cases of isolated STIC identified at RRSO, where staging was undertaken

<sup>#</sup>Recurrence 48 months after RRSO. No staging/chemotherapy after STIC confirmed. Presented with rising CA125 and ascites.

<sup>~</sup>Recurrence 43 months after RRSO. No staging/chemotherapy after STIC confirmed. Presented with rising CA125 and omental deposits.

<sup>£</sup>Recurrence 32 and 42 months after RRSO. No staging/chemotherapy after STIC confirmed.

<sup>§</sup>Recurrence 36 months after RRSO. No staging/chemotherapy after STIC confirmed.

*Timing of recurrence (range 32-48 months) of isolated STIC in the small number of reported cases is not that consistent with a missed metastases that would have necessarily have been identified at staging. One would have expected a missed metastases to present in 12-18 months without further treatment (given what we understand of OC progression through screening and tumour modelling studies), and not a delayed presentation at 3-4 years.*

**Table-4: Clinical trials investigating risk reducing salpingectomy as an alternative surgical strategy for ovarian cancer prevention in women at increased risk of ovarian cancer**

Study	Country	Study design	Population	Sample size	Study arms	Primary outcomes	Secondary outcomes	Follow up	Study Status
PROTECTOR (ISRCTN25173360)	UK	Multicentre, prospective, cohort	BRCA1/BRCA2/RAD51C/RAD51D/BRIP1 mutation carriers or FH of BC-&-OC or OC alone <sup>#</sup> , premenopausal, $\geq 30$ years,	1000	RRESDO RRSO Controls (no surgery)	Sexual function	Endocrine function/menopause; regret/satisfaction; surgical morbidity; QoL/psychological health; intraepithelial carcinomas; invasive cancers; utility scores for ES; cost-effectiveness	3 years (longer term follow up maintained through establishment of a national register)	Recruiting
TUBA (NCT02321228)	Netherlands	Multicentre, prospective, cohort	BRCA1/BRCA2 mutation carriers, premenopausal, $\geq 25$ years	510	RRESDO RRSO	Menopause specific QoL	QoL; sexual function; cancer worry; satisfaction/regret; surgical complications; intraepithelial carcinomas; invasive cancers; CVD risk factors; incidence of CVD; cost-effectiveness	15 years	Recruiting
Radical Fimbriectomy* for Young BRCA Mutation Carriers (NCT01608074)	France	Multicentre, prospective, cohort	BRCA1/BRCA2 mutation carriers or high-risk FH, premenopausal, $\geq 35$ years	123	Radical fimbriectomy	Number of OC/PPC occurring between fimbriectomy and menopause	Morbidity; incidence of intraepithelial/invasive carcinomas at fimbriectomy; incidence and recurrence of BC; rate of DO	15 years	Closed to recruitment
Prophylactic Salpingectomy With Delayed Oophorectomy (NCT01907789)	US	Multicentre, prospective, cohort	BRCA1/BRCA2 mutation carriers, premenopausal, 30-47 years	80	RRESDO RRSO OC screening	Proportion of participants undergoing DO after ES	Acceptability; surgical outcomes; QoL; cancer specific worry; anxiety; sexual function; body image and menopausal symptoms	RRESDO arm 4 years; RRSO arm 1 year OC screening arm 3 years (longer term follow up maintained through annual telephone follow up)	Closed to recruitment
WISP (NCT02760849)	US	Multicentre, prospective, cohort	BRCA1/BRCA2/BRIP1/PALB2/RAD51C/RAD51D/BARD1/MSH2/MSH6/MLH1/PMS2/EPCAM mutation carriers, premenopausal, 30-50 years	300	RRESDO (ISDO) RRSO	Sexual function	QoL	26 years	Recruiting

PROTECTOR - Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal; TUBA - Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers; OC – ovarian cancer; BC – breast cancer; RRESDO – risk reducing early salpingectomy with delayed oophorectomy; RRSO – risk reducing salpingo-oophorectomy; QoL – quality of life; PPC – primary peritoneal cancer; ES – early salpingectomy; DO – delayed oophorectomy; FH – family history; CVD – cardiovascular disease; WISP - The Women Choosing Surgical Prevention Trial, ISDO – Interval Salpingectomy & Delayed Oophorectomy

\*Significant family history defined as:- BRCA negative: >2 individuals with ovarian cancer who are first degree relatives,  $\geq 3$  ovarian cancer case families; BRCA unknown:  $\geq 2$  ovarian cancer case families; Manchester Scoring System (MSS3)  $\geq 15$ ; BOADECIA/BRCAPRO combined BRCA1/BRCA2 probability  $\geq 10\%$

\*Fimbriectomy involves removing the tube, fimbrio-ovarian junction and portion of ovary attached to fimbria (up to one-quarter of ovarian volume is removed).

## Appendix-S1: Search strategy for literature search

<b>Objective</b>	To identify published literature on RRESDO for surgical prevention of OC in women at increased risk.
<b>Data sources</b>	A systematic review of articles with the use of MEDLINE (1946 June 2018), EMBASE (1974 to June 2018), Pubmed (1996 to June 2018), CINAHL (1937 to June 2018), PsychINFO (1806 to June 2018)
<b>Search strategy</b>	27 searches were undertaken
	1. (BRCA).ti,ab
	2. exp "BRCA"/
	3. (BRCA AND "1 OR 2").ti,ab
	4. exp "BRCA AND 1 OR 2"/
	5. (BRCA AND 1).ti,ab
	6. exp " BRCA AND 1"/
	7. (BRCA AND 2).ti,ab
	8. exp "BRCA AND 2"/
	9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8
	10. (SALPINGECTOMY).ti,ab
	11. exp "SALPINGECTOMY"/
	12. (RISK REDUCING SALPINGECTOMY).ti,ab
	13. exp "RISK REDUCING SALPINGECTOMY"/
	14. (EARLY SALPINGECTOMY).ti,ab
	15. exp "EARLY SALPINGECTOMY"/
	16. 10 OR 11 OR 12 OR 13 OR 15
	17. (DELAYED OOPHORECTOMY).ti,ab
	18. exp "DELAYED OOPHORECTOMY"/
	19. (DELAYED OVARIECTOMY).ti,ab
	20. exp "DELAYED OVARIECTOMY"/
	21. 17 OR 18 OR 19 OR 20
	22. (OVARY CANCER).ti,ab
	23. exp "OVARY CANCER"/
	24. (OVARIAN CARCINOMA).ti,ab
	25. exp "OVARIAN CARCINOMA"/
	26. 22 OR 23 OR 24 OR 25
	27. 9 AND 16 AND 21 AND 26
<b>Eligibility criteria</b>	Women at increased risk of OC undergoing RRESDO; full articles in English language.
<b>Data extraction</b>	Citation and abstracts reviewed by author FG. Relevant papers reviewed by RM.
<b>Conclusion</b>	RRSO is the current gold standard for OC risk reduction but has limitations including premature menopause. RRESDO is a two staged surgical alternative for premenopausal women wanting to reduce their OC risk but at the same time avoid the detrimental health sequelae of premature menopause. There is a paucity of published data on outcomes of RRESDO.

RRESDO – risk reducing early salpingectomy with delayed oophorectomy; RRSO – risk reducing early salpingectomy; OC - ovarian cancer



**Figure-S1: Flowchart of study selection**

